HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

Item

http://www.wikidata.org/entity/Q35950913

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@ast

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@en

type

Item

label

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@ast

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@en

prefLabel

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@ast

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@en

P1476

HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

@en

P2093

Elaine Stanford

http://www.w3.org/2001/XMLSchema#string

Jamie Findlow

http://www.w3.org/2001/XMLSchema#string

Joanne White

http://www.w3.org/2001/XMLSchema#string

Kate Soldan

http://www.w3.org/2001/XMLSchema#string

Rosalind Warrington

http://www.w3.org/2001/XMLSchema#string

Sukamal Das

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Prevalence of human papillomavirus antibodies in males and females in England.

Ten years of serological surveillance in England and Wales: methods, results, implications and action.

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

P304

e0150107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0150107

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Mesher

Richard Pebody

Ray Borrow

P577

2016-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297723313

http://www.w3.org/2001/XMLSchema#string

P698

26959232

http://www.w3.org/2001/XMLSchema#string

P932

4784902

http://www.w3.org/2001/XMLSchema#string